PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

BACKGROUND: This randomised, double-blind study compared PF-05280014 (a trastuzumab biosimilar) with reference trastuzumab (Herceptin®) sourced from the European Union (trastuzumab-EU), when each was given with paclitaxel as first-line treatment for HER2-positive metastatic breast cancer. METHODS: B...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Pegram, Mark D., Bondarenko, Igor, Zorzetto, Marina Moreira Costa, Hingmire, Sachin, Iwase, Hirotaka, Krivorotko, Petr V., Lee, Keun Seok, Li, Rubi K., Pikiel, Joanna, Aggarwal, Rajesh, Ewesuedo, Reginald, Freyman, Amy, Li, Ray, Vana, Alicia, Yin, Donghua, Zacharchuk, Charles, Tan-Chiu, Elizabeth
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6342915/
https://ncbi.nlm.nih.gov/pubmed/30568294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0340-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items